Treatment of symptoms of the menopause

An endocrine society clinical practice guideline

Cynthia A. Stuenkel, Susan R. Davis, Anne Gompel, Mary Ann Lumsden, Mohammad H Murad, Jo Ann V Pinkerton, Richard J. Santen

Research output: Contribution to journalArticle

206 Citations (Scopus)

Abstract

Objective: The objective of this document is to generate a practice guideline for the management and treatment of symptoms of the menopause. Participants: The Treatment of Symptoms of the Menopause Task Force included six experts, a methodologist, and a medical writer, all appointed by The Endocrine Society. Evidence: The Task Force developed this evidenced-based guideline using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and the quality of evidence. The Task Force commissioned three systematic reviews of published data and considered several other existing meta-analyses and trials. Consensus Process: Multiple e-mail communications, conference calls, and one face-to-face meeting determined consensus. Committees of The Endocrine Society, representatives from endorsing societies, and members of The Endocrine Society reviewed and commented on the drafts of the guidelines. The Australasian Menopause Society, the British Menopause Society, European Menopause and Andropause Society, the European Society of Endocrinology, and the International Menopause Society (co-sponsors of the guideline) reviewed and commented on the draft. Conclusions: Menopausal hormone therapy (MHT) is the most effective treatment for vasomotor symptoms and other symptoms of the climacteric. Benefits may exceed risks for the majority of symptomatic postmenopausal women who are under age 60 or under 10 years since the onset of menopause. Health care professionals should individualize therapy based on clinical factors and patient preference. They should screenwomenbefore initiatingMHTfor cardiovascular and breast cancer risk and recommend the most appropriate therapy depending on risk/benefit considerations. Current evidence does not justify the use ofMHTto prevent coronary heart disease, breast cancer, or dementia. Other options are available for those with vasomotor symptoms who prefer not to use MHT or who have contraindications because these patients should not useMHT.Low-dose vaginal estrogen and ospemifene provide effective therapy for the genitourinary syndrome of menopause, and vaginal moisturizers and lubricants are available for those not choosing hormonal therapy. All postmenopausal women should embrace appropriate lifestyle measures.

Original languageEnglish (US)
Pages (from-to)3975-4011
Number of pages37
JournalJournal of Clinical Endocrinology and Metabolism
Volume100
Issue number11
DOIs
StatePublished - Nov 1 2015

Fingerprint

Menopause
Practice Guidelines
Hormones
Teleconferencing
Advisory Committees
Health care
Lubricants
Estrogens
Therapeutics
Guidelines
Communication
Consensus
Andropause
Breast Neoplasms
Patient Preference
Practice Management
Postal Service
Coronary Disease
Dementia
Meta-Analysis

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. A. V., & Santen, R. J. (2015). Treatment of symptoms of the menopause: An endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 100(11), 3975-4011. https://doi.org/10.1210/jc.2015-2236

Treatment of symptoms of the menopause : An endocrine society clinical practice guideline. / Stuenkel, Cynthia A.; Davis, Susan R.; Gompel, Anne; Lumsden, Mary Ann; Murad, Mohammad H; Pinkerton, Jo Ann V; Santen, Richard J.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 100, No. 11, 01.11.2015, p. 3975-4011.

Research output: Contribution to journalArticle

Stuenkel, CA, Davis, SR, Gompel, A, Lumsden, MA, Murad, MH, Pinkerton, JAV & Santen, RJ 2015, 'Treatment of symptoms of the menopause: An endocrine society clinical practice guideline', Journal of Clinical Endocrinology and Metabolism, vol. 100, no. 11, pp. 3975-4011. https://doi.org/10.1210/jc.2015-2236
Stuenkel, Cynthia A. ; Davis, Susan R. ; Gompel, Anne ; Lumsden, Mary Ann ; Murad, Mohammad H ; Pinkerton, Jo Ann V ; Santen, Richard J. / Treatment of symptoms of the menopause : An endocrine society clinical practice guideline. In: Journal of Clinical Endocrinology and Metabolism. 2015 ; Vol. 100, No. 11. pp. 3975-4011.
@article{7a631b28efe2424aa1e02eb3a88ff3af,
title = "Treatment of symptoms of the menopause: An endocrine society clinical practice guideline",
abstract = "Objective: The objective of this document is to generate a practice guideline for the management and treatment of symptoms of the menopause. Participants: The Treatment of Symptoms of the Menopause Task Force included six experts, a methodologist, and a medical writer, all appointed by The Endocrine Society. Evidence: The Task Force developed this evidenced-based guideline using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and the quality of evidence. The Task Force commissioned three systematic reviews of published data and considered several other existing meta-analyses and trials. Consensus Process: Multiple e-mail communications, conference calls, and one face-to-face meeting determined consensus. Committees of The Endocrine Society, representatives from endorsing societies, and members of The Endocrine Society reviewed and commented on the drafts of the guidelines. The Australasian Menopause Society, the British Menopause Society, European Menopause and Andropause Society, the European Society of Endocrinology, and the International Menopause Society (co-sponsors of the guideline) reviewed and commented on the draft. Conclusions: Menopausal hormone therapy (MHT) is the most effective treatment for vasomotor symptoms and other symptoms of the climacteric. Benefits may exceed risks for the majority of symptomatic postmenopausal women who are under age 60 or under 10 years since the onset of menopause. Health care professionals should individualize therapy based on clinical factors and patient preference. They should screenwomenbefore initiatingMHTfor cardiovascular and breast cancer risk and recommend the most appropriate therapy depending on risk/benefit considerations. Current evidence does not justify the use ofMHTto prevent coronary heart disease, breast cancer, or dementia. Other options are available for those with vasomotor symptoms who prefer not to use MHT or who have contraindications because these patients should not useMHT.Low-dose vaginal estrogen and ospemifene provide effective therapy for the genitourinary syndrome of menopause, and vaginal moisturizers and lubricants are available for those not choosing hormonal therapy. All postmenopausal women should embrace appropriate lifestyle measures.",
author = "Stuenkel, {Cynthia A.} and Davis, {Susan R.} and Anne Gompel and Lumsden, {Mary Ann} and Murad, {Mohammad H} and Pinkerton, {Jo Ann V} and Santen, {Richard J.}",
year = "2015",
month = "11",
day = "1",
doi = "10.1210/jc.2015-2236",
language = "English (US)",
volume = "100",
pages = "3975--4011",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "11",

}

TY - JOUR

T1 - Treatment of symptoms of the menopause

T2 - An endocrine society clinical practice guideline

AU - Stuenkel, Cynthia A.

AU - Davis, Susan R.

AU - Gompel, Anne

AU - Lumsden, Mary Ann

AU - Murad, Mohammad H

AU - Pinkerton, Jo Ann V

AU - Santen, Richard J.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Objective: The objective of this document is to generate a practice guideline for the management and treatment of symptoms of the menopause. Participants: The Treatment of Symptoms of the Menopause Task Force included six experts, a methodologist, and a medical writer, all appointed by The Endocrine Society. Evidence: The Task Force developed this evidenced-based guideline using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and the quality of evidence. The Task Force commissioned three systematic reviews of published data and considered several other existing meta-analyses and trials. Consensus Process: Multiple e-mail communications, conference calls, and one face-to-face meeting determined consensus. Committees of The Endocrine Society, representatives from endorsing societies, and members of The Endocrine Society reviewed and commented on the drafts of the guidelines. The Australasian Menopause Society, the British Menopause Society, European Menopause and Andropause Society, the European Society of Endocrinology, and the International Menopause Society (co-sponsors of the guideline) reviewed and commented on the draft. Conclusions: Menopausal hormone therapy (MHT) is the most effective treatment for vasomotor symptoms and other symptoms of the climacteric. Benefits may exceed risks for the majority of symptomatic postmenopausal women who are under age 60 or under 10 years since the onset of menopause. Health care professionals should individualize therapy based on clinical factors and patient preference. They should screenwomenbefore initiatingMHTfor cardiovascular and breast cancer risk and recommend the most appropriate therapy depending on risk/benefit considerations. Current evidence does not justify the use ofMHTto prevent coronary heart disease, breast cancer, or dementia. Other options are available for those with vasomotor symptoms who prefer not to use MHT or who have contraindications because these patients should not useMHT.Low-dose vaginal estrogen and ospemifene provide effective therapy for the genitourinary syndrome of menopause, and vaginal moisturizers and lubricants are available for those not choosing hormonal therapy. All postmenopausal women should embrace appropriate lifestyle measures.

AB - Objective: The objective of this document is to generate a practice guideline for the management and treatment of symptoms of the menopause. Participants: The Treatment of Symptoms of the Menopause Task Force included six experts, a methodologist, and a medical writer, all appointed by The Endocrine Society. Evidence: The Task Force developed this evidenced-based guideline using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and the quality of evidence. The Task Force commissioned three systematic reviews of published data and considered several other existing meta-analyses and trials. Consensus Process: Multiple e-mail communications, conference calls, and one face-to-face meeting determined consensus. Committees of The Endocrine Society, representatives from endorsing societies, and members of The Endocrine Society reviewed and commented on the drafts of the guidelines. The Australasian Menopause Society, the British Menopause Society, European Menopause and Andropause Society, the European Society of Endocrinology, and the International Menopause Society (co-sponsors of the guideline) reviewed and commented on the draft. Conclusions: Menopausal hormone therapy (MHT) is the most effective treatment for vasomotor symptoms and other symptoms of the climacteric. Benefits may exceed risks for the majority of symptomatic postmenopausal women who are under age 60 or under 10 years since the onset of menopause. Health care professionals should individualize therapy based on clinical factors and patient preference. They should screenwomenbefore initiatingMHTfor cardiovascular and breast cancer risk and recommend the most appropriate therapy depending on risk/benefit considerations. Current evidence does not justify the use ofMHTto prevent coronary heart disease, breast cancer, or dementia. Other options are available for those with vasomotor symptoms who prefer not to use MHT or who have contraindications because these patients should not useMHT.Low-dose vaginal estrogen and ospemifene provide effective therapy for the genitourinary syndrome of menopause, and vaginal moisturizers and lubricants are available for those not choosing hormonal therapy. All postmenopausal women should embrace appropriate lifestyle measures.

UR - http://www.scopus.com/inward/record.url?scp=84956876614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956876614&partnerID=8YFLogxK

U2 - 10.1210/jc.2015-2236

DO - 10.1210/jc.2015-2236

M3 - Article

VL - 100

SP - 3975

EP - 4011

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 11

ER -